168 related articles for article (PubMed ID: 37872167)
21. Isoginkgetin, a potential CDK6 inhibitor, suppresses
Yao J; Tang S; Shi C; Lin Y; Ge L; Chen Q; Ou B; Liu D; Miao Y; Xie Q; Tang X; Fei J; Yang G; Tian J; Zeng X
Autophagy; 2023 Apr; 19(4):1221-1238. PubMed ID: 36048765
[TBL] [Abstract][Full Text] [Related]
22. NQO1 Mediates Lenvatinib Resistance by Regulating ROS-induced Apoptosis in Hepatocellular Carcinoma.
Xue W; Wang T; Tian WJ; Pang SQ; Zhang HF; Jia WD
Curr Med Sci; 2024 Feb; 44(1):168-179. PubMed ID: 38217831
[TBL] [Abstract][Full Text] [Related]
23. EGFR activation limits the response of liver cancer to lenvatinib.
Jin H; Shi Y; Lv Y; Yuan S; Ramirez CFA; Lieftink C; Wang L; Wang S; Wang C; Dias MH; Jochems F; Yang Y; Bosma A; Hijmans EM; de Groot MHP; Vegna S; Cui D; Zhou Y; Ling J; Wang H; Guo Y; Zheng X; Isima N; Wu H; Sun C; Beijersbergen RL; Akkari L; Zhou W; Zhai B; Qin W; Bernards R
Nature; 2021 Jul; 595(7869):730-734. PubMed ID: 34290403
[TBL] [Abstract][Full Text] [Related]
24. Network Pharmacology-Based Strategy to Investigate the Mechanisms of Lenvatinib in the Treatment of Hepatocellular Carcinoma.
Liu P; Han B; Zhang Y; Wang X
Comput Intell Neurosci; 2022; 2022():7102500. PubMed ID: 35720901
[TBL] [Abstract][Full Text] [Related]
25. Long non-coding RNA CRNDE promotes malignant progression of hepatocellular carcinoma through the miR-33a-5p/CDK6 axis.
Lin C; Xiang Y; Sheng J; Liu S; Cui M; Zhang X
J Physiol Biochem; 2020 Aug; 76(3):469-481. PubMed ID: 32621257
[TBL] [Abstract][Full Text] [Related]
26. USP22-JMJD8 axis promotes Lenvatinib resistance in hepatocellular carcinoma.
Guo J; Zhao J
Biochim Biophys Acta Mol Cell Res; 2024 Jan; 1871(1):119617. PubMed ID: 37898375
[TBL] [Abstract][Full Text] [Related]
27. Upregulation of miR-124-3p by Liver X Receptor Inhibits the Growth of Hepatocellular Carcinoma Cells Via Suppressing Cyclin D1 and CDK6.
Zhong D; Lyu X; Fu X; Xie P; Liu M; He F; Huang G
Technol Cancer Res Treat; 2020; 19():1533033820967473. PubMed ID: 33073697
[TBL] [Abstract][Full Text] [Related]
28. Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK4/6-independent manner.
Hsieh FS; Chen YL; Hung MH; Chu PY; Tsai MH; Chen LJ; Hsiao YJ; Shih CT; Chang MJ; Chao TI; Shiau CW; Chen KF
Mol Oncol; 2017 Aug; 11(8):1035-1049. PubMed ID: 28453226
[TBL] [Abstract][Full Text] [Related]
29. Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling.
Shigesawa T; Maehara O; Suda G; Natsuizaka M; Kimura M; Shimazaki T; Yamamoto K; Yamada R; Kitagataya T; Nakamura A; Suzuki K; Ohara M; Kawagishi N; Umemura M; Nakai M; Sho T; Morikawa K; Ogawa K; Ohnishi S; Sugiyama M; Mizokami M; Takeda H; Sakamoto N
Carcinogenesis; 2021 Feb; 42(1):58-69. PubMed ID: 32449510
[TBL] [Abstract][Full Text] [Related]
30. EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells.
He X; Hikiba Y; Suzuki Y; Nakamori Y; Kanemaru Y; Sugimori M; Sato T; Nozaki A; Chuma M; Maeda S
Sci Rep; 2022 May; 12(1):8007. PubMed ID: 35568782
[TBL] [Abstract][Full Text] [Related]
31. CSN5 silencing reverses sorafenib resistance of human hepatocellular carcinoma HepG2 cells.
Wang H; Qian Z; Zhao H; Zhang X; Che S; Zhang H; Shang H; Bao J; Hao C; Liu J; Li Z
Mol Med Rep; 2015 Sep; 12(3):3902-3908. PubMed ID: 26035694
[TBL] [Abstract][Full Text] [Related]
32. Resistance of Lenvatinib in Hepatocellular Carcinoma.
Guo J; Zhao J; Xu Q; Huang D
Curr Cancer Drug Targets; 2022; 22(11):865-878. PubMed ID: 36267045
[TBL] [Abstract][Full Text] [Related]
33. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
[TBL] [Abstract][Full Text] [Related]
34. miR-214/199a/199a* cluster levels predict poor survival in hepatocellular carcinoma through interference with cell-cycle regulators.
Wang P; Chen S; Fang H; Wu X; Chen D; Peng L; Gao Z; Xie C
Oncotarget; 2016 Jan; 7(1):929-45. PubMed ID: 26498144
[TBL] [Abstract][Full Text] [Related]
35. Ubiquitin-specific protease 1 acts as an oncogene and promotes lenvatinib efficacy in hepatocellular carcinoma by stabilizing c-kit.
Chen Z; Ma Y; Guo Z; Song D; Chen Z; Sun M
Ann Hepatol; 2022; 27(2):100669. PubMed ID: 35045360
[TBL] [Abstract][Full Text] [Related]
36. Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma.
Huang M; Chen C; Geng J; Han D; Wang T; Xie T; Wang L; Wang Y; Wang C; Lei Z; Chu X
Cancer Lett; 2017 Jul; 398():12-21. PubMed ID: 28377178
[TBL] [Abstract][Full Text] [Related]
37. Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC.
Yi C; Chen L; Lin Z; Liu L; Shao W; Zhang R; Lin J; Zhang J; Zhu W; Jia H; Qin L; Lu L; Chen J
Hepatology; 2021 Nov; 74(5):2544-2560. PubMed ID: 34036623
[TBL] [Abstract][Full Text] [Related]
38. RARRES1 inhibits hepatocellular carcinoma progression and increases its sensitivity to lenvatinib through interaction with SPINK2.
Guo Y; Chai B; Zhang H; Chai X; Chen Y; Xu J; Qin L; Chai Y
Biol Direct; 2024 Feb; 19(1):15. PubMed ID: 38388961
[TBL] [Abstract][Full Text] [Related]
39. METTL1-Mediated m7G tRNA Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma.
Huang M; Long J; Yao Z; Zhao Y; Zhao Y; Liao J; Lei K; Xiao H; Dai Z; Peng S; Lin S; Xu L; Kuang M
Cancer Res; 2023 Jan; 83(1):89-102. PubMed ID: 36102722
[TBL] [Abstract][Full Text] [Related]
40. Integrin subunit beta 8 contributes to lenvatinib resistance in HCC.
Hou W; Bridgeman B; Malnassy G; Ding X; Cotler SJ; Dhanarajan A; Qiu W
Hepatol Commun; 2022 Jul; 6(7):1786-1802. PubMed ID: 35238496
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
